Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

詳細記述

保存先:
書誌詳細
出版年:Cureus
主要な著者: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
フォーマット: Artigo
言語:Inglês
出版事項: Cureus 2020
主題:
Radiation Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://ncbi.nlm.nih.gov/pubmed/33094066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10525
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料